Detalles de la búsqueda
1.
TP53-mutated acute myeloid leukemia and myelodysplastic syndrome: biology, treatment challenges, and upcoming approaches.
Ann Hematol
; 103(4): 1049-1067, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37770618
2.
Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
Ann Hematol
; 103(4): 1187-1196, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38291275
3.
Letermovir prophylaxis for cytomegalovirus reactivation in allogeneic hematopoietic cell transplant recipients: Single center Canadian data.
Eur J Haematol
; 112(2): 301-309, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37830403
4.
Impact of cytomegalovirus (CMV) seroconversion pre-allogeneic hematopoietic cell transplantation on posttransplant outcomes.
Eur J Haematol
; 2024 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38880946
5.
Impact of age on hospitalization and outcomes post allogeneic hematopoietic cell transplantation outcome, a single center experience.
Ann Hematol
; 102(4): 917-926, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36820907
6.
Influence of conditioning regimen intensity on outcomes post-allogeneic hematopoietic cell transplantation for acute myeloid leukemia in complete morphological remission.
Eur J Haematol
; 111(4): 553-561, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37461810
7.
Anti-thymocyte globulin and post-transplant cyclophosphamide predisposes to inferior outcome when using cryopreserved stem cell grafts.
Eur J Haematol
; 108(1): 61-72, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34606661
8.
Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors.
Eur J Haematol
; 108(4): 288-297, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34905239
9.
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Br J Haematol
; 193(4): 779-791, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33876423
10.
Pretransplant bone marrow cellularity and blood count recovery are not associated with relapse or survival risk following allogeneic stem cell transplant for AML in CR.
Eur J Haematol
; 107(3): 354-363, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34076909
11.
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option.
Am J Hematol
; 96(2): 179-187, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33108034
12.
Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Acta Haematol
; 144(1): 66-73, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32428903
13.
Safety of two-hour intermittent intravenous infusions of tacrolimus in the allogeneic hematopoietic stem cell transplantation unit.
J Oncol Pharm Pract
; 27(1): 33-39, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32183586
14.
Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Ann Hematol
; 99(6): 1377-1387, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32382774
15.
Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.
Biol Blood Marrow Transplant
; 25(6): 1158-1163, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30654137
16.
Influence of FLT3-ITD and NPM1 status on allogeneic hematopoietic cell transplant outcomes in patients with cytogenetically normal AML.
Eur J Haematol
; 102(4): 368-374, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30706524
17.
Fludarabine and busulfan plus low-dose TBI as reduced intensity conditioning in older patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies.
Ann Hematol
; 97(10): 1975-1985, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29947975
18.
Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
Eur J Haematol
; 100(2): 198-205, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168234
19.
Long-Term Incidence of Secondary Malignancies after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.
Biol Blood Marrow Transplant
; 23(6): 945-951, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28254442
20.
Extramedullary disease at diagnosis of AML does not influence outcome of patients undergoing allogeneic hematopoietic cell transplant in CR1.
Eur J Haematol
; 99(3): 234-239, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28556258